.png){kind=spacer}
Revolutionizing in vitro drug discovery with proprietary chip-free technology for high-throughput, human systemic evaluation.
Current pre-clinical testing protocols are insufficient and lead to a >90% drug failure rate in clinical testing.
Additionally, traditional animal models, such as mice, often fail to reflect human responses accurately and are ineffective for innovative treatments like antibody-drug conjugates.
Our advanced 3D tissue multiplexing mimics the natural physiology of the human body, enabling our partners to study human response to systemic drug delivery in an easy-to-use, high-throughput in vitro model. This enables rapid and accurate pre-clinical evaluation of drugs including small molecules, biologics and antibody-drug conjugates.
How our system works:
1
Compartmentalization of Human Tissues
in Color-Coded Capsules
FluoSphera allows for tissue multiplexing by tagging individual tissue types with a unique color code.
2
Automated Assay Preparation
Multi-Tissue Co-Culture Drug Treatment
Encapsulated tissues are mixed and distributed by an automated robot to form a multi-tissue co-culture. Drug treatments are then performed by a liquid handler.
3
Systemic drug response and
pharmacological dynamics
The multi-tissue co-culture treated with drugs replicates the effects occurring within the human body, including complex systemic communications.
4
High-Content Screening with Multiplexed Image Acquisition for Reliable Prediction of Clinical Response to a Drug
Tissue staining followed by high-content image acquisition to measure the effects of a drug in multiple tissues, simultaneously. Our tissue multiplexing assay enables the integration of the pharmacological dynamics of a drug and reveals details that are otherwise missed on generic testing.
Set of enabling capabilities
The capsule physically separates the different tissues from each other and allows them to exchange soluble factors, similar to how organs interact through blood circulation in the human body. Encapsulated cells aggregate within a few days to form spheroids. The capsule controls the size of the spheroid to ensure oxygen and nutrient diffusion, similar to perfused tissues.
A unique color-coded capsule is assigned to each tissue type so that separate tissues can be recognized without labeling the cells in a multi-tissue culture.
A set of readouts evaluating cytotoxicity and tissue-specific effects were calibrated in-house to provide a robust evaluation of drug effects with several parameters assessed simultaneously.
The strong capability of FluoSphera technology to fit with existing consumables and instruments, along with an automated analysis pipeline for high-content imaging and color multiplexing for tissue and effects identification, allows fast evaluation of compound libraries to provide human-system-relevant datasets.
Variabilities betweenorganoids can generate biased analyses. The spatial positioning of FluoSpheratechnology allows tracking individual organoids within a pool to understanddrug effects before and after treatment, generating unbiased datasets.
After imaging used for drug effect identification, tissues can be sequentially sorted to isolate them for omics downstream assays. This approach provides a holistic view of the drug's mode of action by correlating phenotypic analyses with genomic, proteomic, and lipid profiling.
FluoSphera's technology is a multi-organoid system that combines encapsulated tissues to mimic the complex human system, enabling reliable in vitro drug discovery.
We partner with
